Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

May 21, 2025

Study Completion Date

August 19, 2025

Conditions
Alport SyndromeFocal Segmental Glomerulosclerosis
Interventions
DRUG

R3R01

R3R01 administered orally for 12 weeks

Trial Locations (22)

1200

Investigative site, Brussels

4000

Investigative site, Liège

27511

Investigative Site, Cary

30322

Investigative site, Atlanta

33136

Investigative site, Miami

33431

Investigative site, Boca Raton

33578

Investigative site, Riverview

37075

Investigative site, Göttingen

43235

Investigative site, Columbus

44195

Investigative site, Cleveland

55454

Investigative site, Minneapolis

75015

Investigative site, Paris

75204

Investigative Site, Dallas

77054

Investigative site, Houston

90022

Investigative Site, Los Angeles

02111

Investigative site, Boston

48109-5718

Investigative site, Ann Arbor

02914

Investigative site, East Providence

1105AZ

Investigative site, Amsterdam

6525 GA

Investigative site, Nijmegen

LE5 4PW

Investigative site, Leicester

NG5 1PB

Investigative site, Nottingham

All Listed Sponsors
lead

River 3 Renal Corp.

INDUSTRY